vs
Aclaris Therapeutics, Inc.（ACRS）与碧迪（BDX）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Aclaris Therapeutics, Inc.的4055.6倍（$5.3B vs $1.3M）。碧迪净利率更高（7.3% vs -1528.6%，领先1535.8%）。碧迪同比增速更快（-0.4% vs -85.9%）。碧迪自由现金流更多（$549.0M vs $-13.2M）。过去两年碧迪的营收复合增速更高（2.0% vs -26.5%）
Aclaris Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对免疫疾病、炎症性疾病和皮肤病的创新靶向疗法，核心管线覆盖斑秃、白癜风等未满足临床需求领域，致力于为全球相关患者提供新型治疗选择。
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
ACRS vs BDX — 直观对比
营收规模更大
BDX
是对方的4055.6倍
$1.3M
营收增速更快
BDX
高出85.6%
-85.9%
净利率更高
BDX
高出1535.8%
-1528.6%
自由现金流更多
BDX
多$562.2M
$-13.2M
两年增速更快
BDX
近两年复合增速
-26.5%
损益表 — Q4 2025 vs Q1 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.3M | $5.3B |
| 净利润 | $-19.8M | $382.0M |
| 毛利率 | 58.9% | 45.9% |
| 营业利润率 | -1755.5% | 10.5% |
| 净利率 | -1528.6% | 7.3% |
| 营收同比 | -85.9% | -0.4% |
| 净利润同比 | 79.5% | 24.0% |
| 每股收益（稀释后） | $-0.16 | $1.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACRSBDX
| Q4 25 | $1.3M | $5.3B | ||
| Q3 25 | $3.3M | $5.9B | ||
| Q2 25 | $1.8M | $5.5B | ||
| Q1 25 | $1.5M | $5.3B | ||
| Q4 24 | $9.2M | $5.2B | ||
| Q3 24 | $4.3M | $5.4B | ||
| Q2 24 | $2.8M | $5.0B | ||
| Q1 24 | $2.4M | $5.0B |
净利润ACRSBDX
| Q4 25 | $-19.8M | $382.0M | ||
| Q3 25 | $-14.6M | $493.0M | ||
| Q2 25 | $-15.4M | $574.0M | ||
| Q1 25 | $-15.1M | $308.0M | ||
| Q4 24 | $-96.6M | $303.0M | ||
| Q3 24 | $-7.6M | $400.0M | ||
| Q2 24 | $-11.0M | $487.0M | ||
| Q1 24 | $-16.9M | $537.0M |
毛利率ACRSBDX
| Q4 25 | 58.9% | 45.9% | ||
| Q3 25 | 83.7% | 47.5% | ||
| Q2 25 | 71.0% | 47.8% | ||
| Q1 25 | 65.2% | 42.8% | ||
| Q4 24 | 92.3% | 43.2% | ||
| Q3 24 | 85.0% | 45.7% | ||
| Q2 24 | 77.4% | 46.2% | ||
| Q1 24 | 66.3% | 45.7% |
营业利润率ACRSBDX
| Q4 25 | -1755.5% | 10.5% | ||
| Q3 25 | -519.8% | 11.8% | ||
| Q2 25 | -1035.9% | 16.0% | ||
| Q1 25 | -1242.9% | 10.4% | ||
| Q4 24 | -1082.3% | 8.8% | ||
| Q3 24 | -240.9% | 11.4% | ||
| Q2 24 | -464.7% | 12.1% | ||
| Q1 24 | -789.4% | 14.5% |
净利率ACRSBDX
| Q4 25 | -1528.6% | 7.3% | ||
| Q3 25 | -443.0% | 8.4% | ||
| Q2 25 | -868.3% | 10.4% | ||
| Q1 25 | -1036.8% | 5.8% | ||
| Q4 24 | -1048.3% | 5.9% | ||
| Q3 24 | -174.6% | 7.4% | ||
| Q2 24 | -397.2% | 9.8% | ||
| Q1 24 | -706.5% | 10.6% |
每股收益（稀释后）ACRSBDX
| Q4 25 | $-0.16 | $1.34 | ||
| Q3 25 | $-0.12 | $1.71 | ||
| Q2 25 | $-0.13 | $2.00 | ||
| Q1 25 | $-0.12 | $1.07 | ||
| Q4 24 | $-1.21 | $1.04 | ||
| Q3 24 | $-0.11 | $1.37 | ||
| Q2 24 | $-0.15 | $1.68 | ||
| Q1 24 | $-0.24 | $1.85 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $740.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $103.1M | $25.3B |
| 总资产 | $160.5M | $54.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACRSBDX
| Q4 25 | $20.0M | $740.0M | ||
| Q3 25 | $25.3M | $641.0M | ||
| Q2 25 | $25.4M | $735.0M | ||
| Q1 25 | $30.4M | $667.0M | ||
| Q4 24 | $24.6M | $711.0M | ||
| Q3 24 | $47.7M | $1.7B | ||
| Q2 24 | $22.8M | $4.5B | ||
| Q1 24 | $35.8M | $2.3B |
股东权益ACRSBDX
| Q4 25 | $103.1M | $25.3B | ||
| Q3 25 | $120.1M | $25.4B | ||
| Q2 25 | $131.7M | $25.5B | ||
| Q1 25 | $144.1M | $25.2B | ||
| Q4 24 | $155.6M | $25.2B | ||
| Q3 24 | $130.2M | $25.9B | ||
| Q2 24 | $133.8M | $25.9B | ||
| Q1 24 | $142.0M | $25.6B |
总资产ACRSBDX
| Q4 25 | $160.5M | $54.8B | ||
| Q3 25 | $175.5M | $55.3B | ||
| Q2 25 | $189.1M | $54.9B | ||
| Q1 25 | $198.1M | $54.5B | ||
| Q4 24 | $220.3M | $54.7B | ||
| Q3 24 | $182.4M | $57.3B | ||
| Q2 24 | $161.1M | $55.6B | ||
| Q1 24 | $174.1M | $54.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.1M | $657.0M |
| 自由现金流经营现金流 - 资本支出 | $-13.2M | $549.0M |
| 自由现金流率自由现金流/营收 | -1015.8% | 10.5% |
| 资本支出强度资本支出/营收 | 1.9% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 1.72× |
| 过去12个月自由现金流最近4个季度 | $-47.2M | $2.6B |
8季度趋势，按日历期对齐
经营现金流ACRSBDX
| Q4 25 | $-13.1M | $657.0M | ||
| Q3 25 | $-10.9M | $1.4B | ||
| Q2 25 | $-10.0M | $1.2B | ||
| Q1 25 | $-13.1M | $164.0M | ||
| Q4 24 | $-8.9M | $693.0M | ||
| Q3 24 | $22.0M | $1.2B | ||
| Q2 24 | $-12.3M | $1.3B | ||
| Q1 24 | $-20.8M | $514.0M |
自由现金流ACRSBDX
| Q4 25 | $-13.2M | $549.0M | ||
| Q3 25 | $-11.0M | $1.0B | ||
| Q2 25 | $-10.0M | $1.0B | ||
| Q1 25 | $-13.1M | $35.0M | ||
| Q4 24 | — | $588.0M | ||
| Q3 24 | — | $882.0M | ||
| Q2 24 | $-12.3M | $1.1B | ||
| Q1 24 | $-20.9M | $380.0M |
自由现金流率ACRSBDX
| Q4 25 | -1015.8% | 10.5% | ||
| Q3 25 | -332.1% | 17.0% | ||
| Q2 25 | -563.5% | 19.0% | ||
| Q1 25 | -900.3% | 0.7% | ||
| Q4 24 | — | 11.4% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | -446.0% | 22.4% | ||
| Q1 24 | -873.6% | 7.5% |
资本支出强度ACRSBDX
| Q4 25 | 1.9% | 2.1% | ||
| Q3 25 | 0.7% | 6.0% | ||
| Q2 25 | 1.2% | 3.2% | ||
| Q1 25 | 3.0% | 2.4% | ||
| Q4 24 | 0.0% | 2.0% | ||
| Q3 24 | 0.0% | 5.4% | ||
| Q2 24 | 0.5% | 3.6% | ||
| Q1 24 | 5.6% | 2.7% |
现金转化率ACRSBDX
| Q4 25 | — | 1.72× | ||
| Q3 25 | — | 2.75× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 2.29× | ||
| Q3 24 | — | 2.94× | ||
| Q2 24 | — | 2.66× | ||
| Q1 24 | — | 0.96× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACRS
暂无分部数据
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
